Search Results

You are looking at 51 - 60 of 113 items for :

  • "consolidation therapy" x
  • Refine by Access: All x
Clear All
Full access

Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer

Yuefeng Wang, Xinhua Yu, Nan Zhao, Jiajing Wang, Chi Lin, Enrique W. Izaguirre, Michael Farmer, Gary Tian, Bradley Somer, Nilesh Dubal, David L. Schwartz, Matthew T. Ballo, and Noam A. VanderWalde

therapeutic outcomes in several solid malignancies, including melanoma and non–small cell lung cancer. 34 – 37 In the future, rational combinations of definitive local RT with immunotherapy, as well as consolidative therapies to metastatic sites, might offer

Full access

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, and Ndiya Ogba

cycles of therapy and in some settings, may occur over a duration of up to 8 months. 87 Maintenance The goal of extended maintenance or continuation therapy is to prevent disease relapse after postremission induction and consolidation therapy. Most

Full access

Multiple Myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, and Furhan Yunus

= 121) alone, VAD plus consolidation therapy with dexamethasone/cyclophosphamide/etoposide/cisplatin (DCEP; n = 121), bortezomib/dexamethasone alone (n = 121), or bortezomib/dexamethasone plus consolidation with DCEP (n = 119), followed by autologous SCT

Full access

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry Anderson, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Malin Hultcrantz, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Kenneth Shain, Douglas Sborov, Keith Stockerl-Goldstein, Donna Weber, Jennifer Keller, and Rashmi Kumar

-dose melphalan and then consolidation therapy with the same primary regimen. 86 The addition of bortezomib to thalidomide and dexamethasone significantly improved ORR after primary treatment. After primary therapy, CR/near CR was achieved in 73 patients (31%; 95

Full access

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Kristin Page, Anne F. Reilly, Joanna L. Weinstein, Ana C. Xavier, Nicole R. McMillian, and Deborah A. Freedman-Cass

for most patients are R -CYVE (if not previously received as part of initial therapy) or R -ICE. Consolidation therapy is recommended based on response (see later sections). It is rare for patients who had Group A disease at initial diagnosis to

Full access

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Babis Andreadis, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Julie E. Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E. Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S. Kaminski, Yasmin Karimi, Christopher R. Kelsey, Rebecca King, Susan Krivacic, Ann S. LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

maintenance therapy with ibrutinib + rituximab is an effective induction therapy for patients aged <66 years, and consolidation therapy with HDT/ASCR could be avoided in this group of patients. Based on the preliminary results of this study, the NCCN

Full access

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019

Featured Updates to the NCCN Guidelines

Patrick A. Brown, Matthew Wieduwilt, Aaron Logan, Daniel J. DeAngelo, Eunice S. Wang, Amir Fathi, Ryan D. Cassaday, Mark Litzow, Anjali Advani, Patricia Aoun, Bhavana Bhatnagar, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Peter F. Coccia, Steven E. Coutre, Nitin Jain, Suzanne Kirby, Arthur Liu, Stephanie Massaro, Ryan J. Mattison, Olalekan Oluwole, Nikolaos Papadantonakis, Jae Park, Jeffrey E. Rubnitz, Geoffrey L. Uy, Kristina M. Gregory, Ndiya Ogba, and Bijal Shah

randomly assigned older patients with Ph-positive ALL (N=55; age 54–79 years) to induction therapy with imatinib versus chemotherapy alone, followed by imatinib-containing consolidation therapy, the estimated 2-year OS rate was 42%; no significant

Full access

Multiple Myeloma, Version 2.2016

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

, median progression-free survival (PFS) was modestly but not statistically significantly prolonged, with 36.0 months with bortezomib and dexamethasone versus 29.7 months with VAD. 76 Use of DCEP as consolidation therapy after primary therapy did not have

Full access

Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?

Farhad Ravandi and Jeffrey L. Jorgensen

induction and consolidation therapy. On multivariate analysis, postconsolidation MRD status independently affected relapse rate, overall survival, and relapse-free survival ( P < .001, for all comparisons). 21 Vinditti et al., 22 , 23 recently confirmed

Full access

Experimental Therapies and Clinical Trials in Bone Sarcoma

Rashmi Chugh

-dose therapy for patients with newly diagnosed localized or metastatic EWS (NCT00020566). After initial induction chemotherapy and local therapy, patients undergo risk-stratified consolidation therapy ( Figure 1 ). Patients who experience poor response (R2) are